Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Sysmex Corporation and Hitachi High-Tech Corporation Join Forces for Advancement in Genetic Testing System Development

NextEdge Admin

02 Apr 2024

2 min 30 sec

Hitachi High-Tech Corporation,Genetic Testing

Sysmex Corporation and Hitachi High-Tech Corporation have announced a collaboration to develop genetic testing systems based on capillary electrophoresis sequencers (CE sequencers). The decision follows joint research since the feasibility study (FS) agreement in August 2023. The aim is to create more efficient and cost-effective genetic testing systems to enable widespread clinical use, focusing on optimal genetic testing for individual diseases.

The genetic testing field has seen active development using next-generation sequencers (NGS). However, challenges such as shorter measurement times and reduced running costs have prompted the need for new genetic testing systems suitable for widespread clinical adoption.

The collaboration leverages Hitachi High-Tech’s CE sequencer technology and Sysmex’s expertise in NGS reagent development and analysis technology. After achieving milestones in the FS agreement, the companies will now collaborate on developing genetic testing systems, initially focusing on oncology applications before expanding to other disease areas. Hitachi High-Tech will seek approval for CE sequencers as medical devices, while Sysmex will pursue development and regulatory approval for testing reagents and analysis software.

Sysmex has been actively working towards the clinical realization of genomic medicine, gaining regulatory approval and insurance coverage for cancer genomic profiling and gene panel testing systems in Japan. Hitachi High-Tech aims to contribute to personalized medicine and improved quality of life through molecular diagnostics.

The collaboration aims to maximize the use of individual technologies and knowhow to achieve the spread of new genetic testing systems with shorter measurement times and reduced running costs, ultimately supporting optimal medical care tailored to each